Parallel Advisors’s Passage Bio PASG Stock Holding History

Parallel Advisors’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16	Closed	-$126	–	4038
2026 Q1	$126	Hold	16	–	–	﹤0.01%	3779
2025 Q4	$189	Hold	16	–	–	﹤0.01%	3518
2025 Q3	$128	Buy	+16	New	+$111	﹤0.01%	3470
2022 Q1	–	Sell	-62	Closed	-$8K	–	3189
2021 Q4	$8K	Buy	62 +56	+933%	+$9.14K	﹤0.01%	2218
2021 Q3	$1K	Buy	+6	New	+$1.43K	﹤0.01%	2925

Other funds holding PASG

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $291M AUM 19.43% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers Boston, Massachusetts $104M AUM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Parallel Advisors's PASG Position: Q2 2026 in Review

Parallel Advisors sold out of Passage Bio (PASG) in Q2 2026, closing a stake of 16 shares — an estimated $126 sold.

Parallel Advisors first reported a position in PASG in Q3 2021 and held it in 5 quarters. The position peaked at $8K in Q4 2021. 29 funds tracked by Wall St. Rank hold PASG as of Q2 2026.

Parallel Advisors reported no remaining Passage Bio position as of Q2 2026 after selling out during the quarter.
Parallel Advisors sold 16 Passage Bio shares in Q2 2026, an estimated $126.
Parallel Advisors first reported a position in Passage Bio in Q3 2021 and held it in 5 quarters.
Parallel Advisors's Passage Bio position peaked at $8K in Q4 2021.
29 funds tracked by Wall St. Rank held Passage Bio as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.